Apexian Pharmaceuticals has brought on Richard Messmann as the biotech company’s chief medical officer. Before joining Indianapolis-based Apexian, Messmann was chief medical officer of ProNAi Therapeutics in Vancouver, Canada. His 25 years of cancer drug development experience includes stints at Eli Lilly & Co. (NYSE: [[ticker:LLY]]), Endocyte (NASDAQ: [[ticker:ECYT]]), Great Lakes Cancer Institute at Michigan State University, and the National Cancer Institute.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
